Bausch + Lomb Announces Two Board of Directors Appointments

This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentVAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed to its board of directors. The appointments are effective Jan. 1, 2026, and following changes announced in August 2025 the board will be comprised of 10 directors.Sign In or Create an AccountEmail AddressContinueor View more offersArticle content“Eddie is one of the most prominent and respected ophthalmologists in the world, and Steve delivered tremendous financial growth as the longtime CEO of a Fortune 10 company,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “With decades of hard-earned insight, they will help shape the future of Bausch + Lomb as we accelerate our strategy and pursue the significant opportunities ahead.”Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentArticle contentAbout Eduardo C. Alfonso Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentEduardo C. Alfonso, MD, is an ophthalmologist and internationally recognized expert in corneal and external eye diseases. He serves as director of the Bascom Palmer Eye Institute and chair of the Department of Ophthalmology at the University of Miami Miller School of Medicine and holds the Kathleen and Stanley J. Glaser Chair in Ophthalmology.Article contentDr. Alfonso earned his bachelor’s degree and medical degree from Yale University. He completed his ophthalmology residency at the Bascom Palmer Eye Institute, followed by advanced fellowships at Harvard Medical School in cornea, external disease and ophthalmic pathology.Article contentHe joined the Bascom Palmer faculty in 1986 and became a tenured professor in 1998. Since 2007, he has led the institute, which is consistently ranked among the top ophthalmology centers in the United States. Dr. Alfonso is known for his research and clinical expertise in corneal infections, transplants and keratoprosthesis (artificial cornea), has authored hundreds of scientific publications and has received major awards from national and international ophthalmology organizations.Article contentAbout Steven H. Collis Article contentSteven H. Collis is best known for his long leadership of Cencora, Inc., one of the world’s largest pharmaceutical distribution and health care services companies. Collis earned a Bachelor of Commerce from the University of the Witwatersrand in Johannesburg, South Africa, and joined the company that would become Cencora in the mid-1990s, helping build its specialty pharmaceuticals business and rising through senior executive roles.Article contentHe became President and CEO in 2011 and served in that role through 2024, during which time the company’s annual revenue more than tripled and its global presence expanded significantly through strategic acquisitions and partnerships. Under his leadership, the company rebranded from AmerisourceBergen to Cencora in 2023 to reflect its global reach. Collis then transitioned to Executive Chairman of the Board, continuing to influence company strategy until he stepped down in late 2025.Article contentCollis currently serves on the board of Elevance Health, a managed health care and insurance company.Article contentAbout Bausch + Lomb Article contentOur mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more atArticle contentwww.bausch.comArticle contentand connect with us onArticle contentFacebookArticle content,Article contentInstagramArticle content,Article contentLinkedInArticle content,Article contentXArticle contentandArticle contentYouTubeArticle content.Article content© 2025 Bausch + Lomb.Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content https://www.businesswire.com/news/home/20251217691096/en/Article contentArticle contentContactsArticle contentMedia Contact: Article contentArticle contentT.J. CrawfordArticle contentArticle contenttj.crawford@bausch.com Article contentArticle content(908) 705-2851Article contentInvestor Contact: George Gadkowski george.gadkowski@bausch.com (877) 354-3705 (toll free)Article content#distroArticle contentTrending 'Why let one person in the States change your life?' For Canadian snowbirds, the stay or go dilemma gets complicated Real Estate Canada's population declines for the first time since the pandemic News Expect 'dramatically higher' oil prices in 2026, says Eric Nuttall Oil & Gas Is a $2.75 million portfolio enough for Halifax empty nesters to retire early?

Personal Finance Terence Corcoran: The new Rogers v. Rogers play gets a BS rating FP Comment Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. 'Why let one person in the States change your life?' For Canadian snowbirds, the stay or go dilemma gets complicated Real Estate Canada's population declines for the first time since the pandemic News Expect 'dramatically higher' oil prices in 2026, says Eric Nuttall Oil & Gas Is a $2.75 million portfolio enough for Halifax empty nesters to retire early?

Personal Finance Terence Corcoran: The new Rogers v. Rogers play gets a BS rating FP Comment